Low Vitamin D Levels Predict Outcomes of COVID-19 in Patients with Both Severe and Non-severe Disease at Hospitalization
Overview
Authors
Affiliations
Purpose: Low vitamin D in COVID-19 have been related to worse outcomes. However, most of the studies conducted so far were not-controlled and retrospective, including biases potentially influencing this association. We evaluated 25(OH)vitamin D levels of patients with both severe and non-severe disease at hospital-admission, and in a cohort of control subjects. Moreover, we evaluated sACE-2 levels to investigate the mechanisms underlying the association between vitamin D and COVID-19.
Methods: COVID-19 patients were enrolled in a matched for age, sex and comorbidities 1:1-ratio based on the presence/or not of respiratory-distress/severe-disease at hospital-admission. Control matched subjects were enrolled from an outpatient-setting.
Results: Seventy-three COVID-19 patients (36 severe and 37 non-severe) and 30 control subjects were included. We observed a higher vitamin D deficiency (<20 ng/mL) prevalence in COVID-19 patients than control subjects (75% vs 43%). No differences were found regarding 25(OH)vitamin D and sACE-2 levels between patients with and without severe-disease at study entry. During the disease-course, in the severe group a life-threatening disease occurred in 17 patients (47.2%), and, in the non-severe group, a worsening disease occurred in 10 (27%). 25(OH)vitamin D levels, at admission, were negatively correlated with sACE-2 levels, and were lower in patients whose disease worsened as compared to those in whom it did not, independently from the disease severity at admission. In multivariate-analysis, lower 25(OH)vitamin D resulted as an independent risk factor for disease worsening.
Conclusions: 25(OH)vitamin D levels at hospital-admission strongly predicted the occurrence of worsening outcomes in COVID-19 independently of the disease severity at presentation.
Morphometric vertebral fractures at hospitalization associate with Long COVID occurrence.
Di Filippo L, Doga M, Mangini F, Gifuni L, Sahagun S, Querini P J Endocrinol Invest. 2025; .
PMID: 39932650 DOI: 10.1007/s40618-025-02544-1.
Huang L, Song Z, Lu C, Wang S, Guo C, Lai X Front Nutr. 2025; 11():1461485.
PMID: 39839285 PMC: 11745885. DOI: 10.3389/fnut.2024.1461485.
Hamed E, Abdelhady S, Al-Touny S, Kishk R, Mohamed M, Rageh F BMC Med Genomics. 2024; 17(1):284.
PMID: 39623417 PMC: 11613538. DOI: 10.1186/s12920-024-02018-y.
Wang M, Wu Y, Xiang Z, Zhang Y, Huang T, Chen B Front Nutr. 2024; 11:1502835.
PMID: 39600723 PMC: 11588496. DOI: 10.3389/fnut.2024.1502835.
Beyond Antivirals: Alternative Therapies for Long COVID.
Livieratos A, Gogos C, Akinosoglou K Viruses. 2024; 16(11).
PMID: 39599909 PMC: 11599064. DOI: 10.3390/v16111795.